BAP1 and malignant pleural mesothelioma: Based on these results, Tazemetostat has been used in a phase-II study for the treatment of malignant pleural mesothelioma patients characterized by BAP1 [breast cancer 1 (BRCA1) associated protein 1] inactivation [121] showing a good tolerability to the drug.